<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vestar</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник аритмологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Arrhythmology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-8641</issn><issn pub-type="epub">2658-7327</issn><publisher><publisher-name>НАО «Инкарт»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35336/VA-2021-3-28-36</article-id><article-id custom-type="elpub" pub-id-type="custom">vestar-991</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Фибрилляция предсердий и факторы риска инсульта у пациентов с имплантированными сердечными устройствами</article-title><trans-title-group xml:lang="en"><trans-title>Atrial fibrillation and stroke risk factors in patients with cardiac implantable electronic devices</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9011-2879</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рахимова</surname><given-names>И. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakhimova</surname><given-names>I. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Семей, ул. Абая, д. 103</p></bio><bio xml:lang="en"><p>Semey, 103 Abaya str.</p></bio><email xlink:type="simple">idalya111@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1886-0538</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хайбуллин</surname><given-names>Т. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Khaibullin</surname><given-names>T. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Семей, ул. Абая, д. 103</p></bio><bio xml:lang="en"><p>Semey, 103 Abaya str.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1004-2162</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковальчук</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalchuk</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кембридж CB2 1TN, переулок Тринити</p></bio><bio xml:lang="en"><p>Cambridge CB2 1TN, Trinity Lane</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6315-5016</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдрахманов</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdrakhmanov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Нур-Султан, пр. Туран, д. 38.</p></bio><bio xml:lang="en"><p>Nur-Sultan, 38 Turan avenue</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НАО Медицинский университет Семей</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>NJSC Semey Medical University</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кембриджский Университет</institution><country>Великобритания</country></aff><aff xml:lang="en"><institution>University of Cambridge</institution><country>United Kingdom</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный научный кардиохирургический центр</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>National research cardiac surgery center</institution><country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>26</day><month>10</month><year>2021</year></pub-date><volume>28</volume><issue>3</issue><fpage>28</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рахимова И.Р., Хайбуллин Т.Н., Ковальчук В.В., Абдрахманов А.С., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Рахимова И.Р., Хайбуллин Т.Н., Ковальчук В.В., Абдрахманов А.С.</copyright-holder><copyright-holder xml:lang="en">Rakhimova I.R., Khaibullin T.N., Kovalchuk V.V., Abdrakhmanov A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestar.elpub.ru/jour/article/view/991">https://vestar.elpub.ru/jour/article/view/991</self-uri><abstract><sec><title>Цель</title><p>Цель. Определить долю и бремя вновь возникшей фибрилляции предсердий (ФП) у пациентов с имплантированными сердечными устройствами и без предшествующей ФП, а также оценить частоту встречаемости факторов риска инсульта у пациентов с ФП.</p></sec><sec><title>Методы исследования</title><p>Методы исследования. Были проанализированы истории болезни 111 пациентов с имплантированными сердечными устройствами с функцией удаленного мониторинга. ФП, диагностированная устройством, была интерпретирована врачом-аритмологом и отобраны случаи достоверной ФП. Было проведено сопоставление группы пациентов с ФП и без нее по ряду факторов. С целью уточнения влияния факторов риска на продолжительность ФП, все случаи ФП были разделены на 3 категории в зависимости от бремени ФП за сутки. В первую группу вошли пациенты с бременем ФП за сутки 0,1% и менее (n=10, (45,5%)), во вторую - от 0,3% до 12,2% (n=7, (31,8%)), и в третью группу со 100% (n=5, (22,7%)). Пациенты с бременем 0,2% и 12,3-99,9% отсутствовали.</p></sec><sec><title>Результаты</title><p>Результаты. Впервые выявленная ФП была зарегистрирована в 19,8% случаев. Риск инсульта среди этих пациентов был высоким - 2 [1; 3] балла по шкале CHA2 DS2 -VASc у мужчин, и 3 [2,75; 3,75] балла у женщин. Артериальная гипертензия (АГ) 2 и 3 степени была зарегистрирована у всех пациентов в группе с бременем ФП 100% за сутки. Что статистически значимо отличалось от 2 других групп (р=0,043). В группе с бременем ФП 100% уровни NT-proBNP, D-димера и креатинина были статистически значимо выше, чем в остальных группах (р=0,037, р=0,031 и р=0,036 соответственно). При анализе зависимости уровня креатинина от наличия ФП площадь под ROC-кривой составила 0,653 [95% ДИ: 0,528-0,779] (p=0,017). Частота стимуляции правого желудочка у пациентов с ИКД была выше в группе пациентов с ФП.</p></sec><sec><title>Заключение</title><p>Заключение. ФП встречается у 1/5 пациентов с имплантированными сердечными устройствами. Все пациенты с ФП являлись потенциальными кандидатами на терапию антикоагулянтами из-за высокого риска инсульта. Суточное бремя ФП положительно коррелирует с наличием и степенью АГ, а также с маркерами дисфункции почек, хронической сердечной недостаточности и тромбоза. Повышенный уровень креатинина является предиктором развития ФП.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose. Determination the proportion and burden of new-onset atrial fibrillation (AF) in patients with cardiac implantable electronic devices (CIED) and without prior AF and assessing the incidence of risk factors for stroke in patients with AF.</p></sec><sec><title>Methods</title><p>Methods. The medical history of 111 patients with CIED with remote monitoring function were analyzed. AF diagnosed by the device was interpreted by an arrhythmologist and cases of significant AF were selected. The group of patients with and without AF was compared for several factors. To clarify the influence of risk factors on the duration of AF, all AF cases were divided into 3 categories depending on the AF burden per day. The first group included patients with an AF burden per day of 0.1% or less (n=10, (45.5%)), the second - from 0.3% to 12.2% (n=7, (31.8%)), and the third group - with 100% (n=5, (22.7%)). Patients with a burden of 0.2%, 12.3-99.9% were absent.</p></sec><sec><title>Results</title><p>Results. Newly diagnosed AF was registered in 19.8% of cases. The risk of stroke among these patients was high - 2 [1; 3] points on the CHA2 DS2 -VASc for men, and 3 [2,75; 3,75] points for women. Hypertension of 2 and 3 degrees was recorded in all patients in the group with an AF burden of 100% per day. That significantly differed from the other 2 groups (p=0.043). In the group with an AF burden of 100%, the levels of NT-proBNP, D-dimer, and creatinine were significantly higher than in the other groups (p=0.037, p=0.031 and p=0.036, respectively). When analyzing the dependence of creatinine level on the presence of AF, the area under the ROC-curve was 0.653 with 95% confidence interval 0.528-0.779 (p=0.017). The proportion of right ventricular pacing in patients with ICD was higher in the group of patients with AF.</p></sec><sec><title>Conclusion</title><p>Conclusion. AF occurs in 1/5 of patients with CIED. All patients with AF were potential candidates for anticoagulation due to their high risk of stroke. The daily burden of AF is positively correlated with the presence and degree of hypertension, as well as with markers of renal dysfunction, chronic heart failure, and thrombosis. Elevated creatinine levels are a predictor of AF.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>риск инсульта</kwd><kwd>предикторы фибрилляции предсердий</kwd><kwd>имплантированные сердечные устройства</kwd><kwd>кардиовертер-дефибриллятор</kwd><kwd>сердечная ресинхронизирующая терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>risk of stroke</kwd><kwd>predictors of atrial fibrillation</kwd><kwd>cardiac implantable electronic devices</kwd><kwd>cardioverter defibrillator</kwd><kwd>cardiac resynchronization therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">January CT, Wann LS, Calkins H, et al. 2019 AHA/ ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;139: 2502-2512. https://doi.org/10.1161/CIRCULATIONAHA.118.038988.</mixed-citation><mixed-citation xml:lang="en">January CT, Wann LS, Calkins H, et al. 2019 AHA/ ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;139: 2502-2512. https://doi.org/10.1161/CIRCULATIONAHA.118.038988.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Benussi S, Kotecha D, et al. Authors/Task Force Members, Document Reviewers:. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;38: 2893-2962.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Benussi S, Kotecha D, et al. Authors/Task Force Members, Document Reviewers:. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;38: 2893-2962.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dilaveris PE, Kennedy HL. Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact. Clin Cardiol. 2017;40(6): 413-418. https://doi.org/10.1002/ clc.22667. Epub 2017 Mar 8. PMID: 28273368; PMCID: PMC6490532.</mixed-citation><mixed-citation xml:lang="en">Dilaveris PE, Kennedy HL. Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact. Clin Cardiol. 2017;40(6): 413-418. https://doi.org/10.1002/clc.22667. Epub 2017 Mar 8. PMID: 28273368; PMCID: PMC6490532.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5): 373-498 https://doi. org/10.1093/eurheartj/ehaa612.</mixed-citation><mixed-citation xml:lang="en">Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5): 373-498 https://doi.org/10.1093/eurheartj/ehaa612.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Jefairi N, Burri H. Relevance of guideline-based ICD indications to clinical practice. Indian Heart J. 2014;66: S82-S87. https://doi.org/10.1016/j.ihj.2013.11.006.</mixed-citation><mixed-citation xml:lang="en">Al-Jefairi N, Burri H. Relevance of guideline-based ICD indications to clinical practice. Indian Heart J. 2014;66: S82-S87. https://doi.org/10.1016/j.ihj.2013.11.006.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lawin D, Stellbrink C. Change in indication for cardiac resynchronization therapy? Eur J Cardiothorac Surg. 2019;55: i11-i16. https://doi.org/10.1093/ejcts/ezy488.</mixed-citation><mixed-citation xml:lang="en">Lawin D, Stellbrink C. Change in indication for cardiac resynchronization therapy? Eur J Cardiothorac Surg. 2019;55: i11-i16. https://doi.org/10.1093/ejcts/ezy488.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zacà V, Marcucci R, Parodi G, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17(6): 840-54. https://doi.org/10.1093/europace/euu357.</mixed-citation><mixed-citation xml:lang="en">Zacà V, Marcucci R, Parodi G, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17(6): 840-54. https://doi.org/10.1093/europace/euu357.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Boriani G, Glotzer TV, Ziegler PD, et al. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm. 2018;15(3): 376-383. https://doi.org/10.1016/j. hrthm.2017.11.007.</mixed-citation><mixed-citation xml:lang="en">Boriani G, Glotzer TV, Ziegler PD, et al. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm. 2018;15(3): 376-383. https://doi.org/10.1016/j. hrthm.2017.11.007.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of &gt;10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014;35(8): 508-16. https://doi.org/10.1093/eurheartj/eht491.</mixed-citation><mixed-citation xml:lang="en">Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of &gt;10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014;35(8): 508-16. https://doi.org/10.1093/eurheartj/eht491.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17): 1339-1344. https://doi.org/10.1093/eurheartj/ehx042.</mixed-citation><mixed-citation xml:lang="en">Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17): 1339-1344. https://doi.org/10.1093/eurheartj/ehx042.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Deharo JC, Djiane P. Home Monitoring: what can we expect in the future? Clin Res Cardiol. 2006;95: 36-9. https://doi.org/10.1007/s00392-006-1307-5.</mixed-citation><mixed-citation xml:lang="en">Deharo JC, Djiane P. Home Monitoring: what can we expect in the future? Clin Res Cardiol. 2006;95: 36-9. https://doi.org/10.1007/s00392-006-1307-5.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira M, Fernandes M, Primo J, et al. Remote versus face-to-face monitoring for implantable cardiac devices: rationale and design of the PORTLink (PORTuguese Research on Telemonitoring with CareLink) trial. Rev Port Cardiol. 2013;32(12): 957-64. https://doi.org/10.1016/j.repc.2013.06.009.</mixed-citation><mixed-citation xml:lang="en">Oliveira M, Fernandes M, Primo J, et al. Remote versus face-to-face monitoring for implantable cardiac devices: rationale and design of the PORTLink (PORTuguese Research on Telemonitoring with CareLink) trial. Rev Port Cardiol. 2013;32(12): 957-64. https://doi.org/10.1016/j.repc.2013.06.009.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Nieuwlaat R, Capucci A, Camm AJ, et al. European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22): 2422-34. https://doi.org/10.1093/eurheartj/ ehi505.</mixed-citation><mixed-citation xml:lang="en">Nieuwlaat R, Capucci A, Camm AJ, et al. European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22): 2422-34. https://doi.org/10.1093/eurheartj/ ehi505.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cleland JG, Swedberg K, Follath F, et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5): 442-63. https://doi.org/10.1016/s0195- 668x(02)00823-0.</mixed-citation><mixed-citation xml:lang="en">Cleland JG, Swedberg K, Follath F, et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5): 442-63. https://doi.org/10.1016/s0195- 668x(02)00823-0.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Khan MA, Ahmed F, Neyses L, et al. Atrial fibrillation in heart failure: The sword of Damocles revisited. World J Cardiol. 2013;5(7): 215-27. https://doi.org/10.4330/wjc. v5.i7.215.</mixed-citation><mixed-citation xml:lang="en">Khan MA, Ahmed F, Neyses L, et al. Atrial fibrillation in heart failure: The sword of Damocles revisited. World J Cardiol. 2013;5(7): 215-27. https://doi.org/10.4330/wjc. v5.i7.215.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Кутырина ИМ, Швецов МЮ. Возможности лечения почечной артериальной гипертонии. Качество жизни. Медицина. 2006;4(15): 78-89.</mixed-citation><mixed-citation xml:lang="en">Kutyrina IM, Shveczov MYu. Vozmozhnosti lecheniya pochechnoj arterial`noj gipertonii. Kachestvo zhizni. Mediczina. 2006;4(15): 78- 89 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев ВС, Кобалава ЖД. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер. 2002;11 (3): 16-18.</mixed-citation><mixed-citation xml:lang="en">Moiseev VS, Kobalava ZhD. Kardiorenal`ny`j sindrom (pochechny`j faktor i povy`shenie riska serdechno-sosudisty`kh zabolevanij). Klin farmak ter. 2002;11(3): 16-18 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10): 1987- 96. https://doi.org/10.1016/j.jacc.2005.11.084.</mixed-citation><mixed-citation xml:lang="en">Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10): 1987- 96. https://doi.org/10.1016/j.jacc.2005.11.084.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. Journal of Hypertension. 2010;28(8): 1738-1744. https://doi.org/10.1097/ hjh.0b013e32833a7dfe.</mixed-citation><mixed-citation xml:lang="en">Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. Journal of Hypertension. 2010;28(8): 1738-1744. https://doi.org/10.1097/ hjh.0b013e32833a7dfe.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal N, Zelnick LR, Alonso A, et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12(9): 1386-1398. https://doi.org/10.2215/CJN.01860217.</mixed-citation><mixed-citation xml:lang="en">Bansal N, Zelnick LR, Alonso A, et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12(9): 1386-1398. https://doi.org/10.2215/CJN.01860217.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Watanab H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. American Heart Journal. 2009;158(4): 629-636. https://doi.org/10.1016/j.ahj.2009.06.031.</mixed-citation><mixed-citation xml:lang="en">Watanab H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. American Heart Journal. 2009;158(4): 629-636. https:// doi.org/10.1016/j.ahj.2009.06.031.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yashiro Y, Arimoto T, Hashimoto N, et al. Predictors of left atrial coagulation activity among paroxysmal atrial fibrillation patients. Circ J. 2015;79(1): 61-9. https://doi.org/10.1253/circj.CJ-14-0630..</mixed-citation><mixed-citation xml:lang="en">Yashiro Y, Arimoto T, Hashimoto N, et al. Predictors of left atrial coagulation activity among paroxysmal atrial fibrillation patients. Circ J. 2015;79(1): 61-9. https://doi.org/10.1253/circj.CJ-14-0630.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010;55(20): 2225-31. https://doi.org/10.1016/j. jacc.2009.12.049.</mixed-citation><mixed-citation xml:lang="en">Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010;55(20): 2225-31. https://doi.org/10.1016/j. jacc.2009.12.049.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zorlu A, Akkaya E, Altay H, et al. The relationship between D-dimer level and the development of atrial fibrillation in patients with systolic heart failure. J Thromb Thrombolysis. 2012;33(4): 343-8. https://doi.org/10.1007/ s11239-011-0656-8. PMID: 22139027.</mixed-citation><mixed-citation xml:lang="en">Zorlu A, Akkaya E, Altay H, et al. The relationship between D-dimer level and the development of atrial fibrillation in patients with systolic heart failure. J Thromb Thrombolysis. 2012;33(4): 343-8. https://doi.org/10.1007/ s11239-011-0656-8. PMID: 22139027.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sweeney MO, Hellkamp AS, Ellenbogen KA et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107: 2932 -7.</mixed-citation><mixed-citation xml:lang="en">Sweeney MO, Hellkamp AS, Ellenbogen KA et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107: 2932 -7.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Pastore G, Zanon F, Baracca E et al. The risk of atrial fibrillation during right ventricular pacing. Europace. 2016;18(3): 353-8. https://doi.org/10.1093/europace/euv268.</mixed-citation><mixed-citation xml:lang="en">Pastore G, Zanon F, Baracca E et al. The risk of atrial fibrillation during right ventricular pacing. Europace. 2016;18(3): 353-8. https://doi.org/10.1093/europace/euv268.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
